本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Allogene Therapeutics Inc.

1.23
0.0000
盤後1.230.00000.00%19:35 EST
成交量:236.98萬
成交額:295.71萬
市值:2.76億
市盈率:-1.26
高:1.28
開:1.22
低:1.21
收:1.23
52周最高:3.78
52周最低:0.8621
股本:2.25億
流通股本:1.68億
量比:1.02
換手率:1.41%
股息:- -
股息率:- -
每股收益(TTM):-0.9781
每股收益(LYR):-1.3222
淨資產收益率:-54.43%
總資產收益率:-27.34%
市淨率:0.88
市盈率(LYR):-0.93

資料載入中...

2022/02/23

重要事件披露

8-K - Current report
2022/02/23

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2022/02/23

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/10

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/18

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/10/04

持股變動聲明

4 - Statement of changes in beneficial ownership of securities
2021/09/20

持股變動聲明

3 - Initial statement of beneficial ownership of securities
2021/09/17

持股變動聲明

4 - Statement of changes in beneficial ownership of securities
2021/09/09

持股變動聲明

4 - Statement of changes in beneficial ownership of securities
2021/08/23

持股變動聲明

4 - Statement of changes in beneficial ownership of securities
2021/08/17

持股變動聲明

4 - Statement of changes in beneficial ownership of securities
2021/08/03

持股變動聲明

3 - Initial statement of beneficial ownership of securities
2021/08/03

持股變動聲明

3 - Initial statement of beneficial ownership of securities
2021/08/03

持股變動聲明

4 - Statement of changes in beneficial ownership of securities
2021/08/03

持股變動聲明

4 - Statement of changes in beneficial ownership of securities
2021/07/16

持股變動聲明

4 - Statement of changes in beneficial ownership of securities